Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia : a prospective study
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
IMPORTANCE: Identifying undetected clinical signs is imperative in the prevention of SARS-CoV-2.
OBJECTIVE: To establish the prevalence of clinical gustatory and olfactory dysfunctions in patients with COVID-19 pneumonia. Clinical outcomes and recovery rates associated with gustatory and olfactory dysfunctions were also assessed.
DESIGN: A prospective study was performed in 80 patients admitted to Hospital Clínic of Barcelona (Spain) for COVID-19 pneumonia. Patients were re-evaluated in the ward daily until discharge. Gustatory and olfactory dysfunction symptoms were retrospectively collected from emergency room (ER) charts after first assessments. Follow-up was performed in telemedicine consultation.
SETTING: The single-centre study was performed in a hospitalisation ward at a university hospital.
PARTICIPANTS: Consecutive patients meeting hospitalisation criteria for COVID-19 pneumonia were eligible. Study exclusion criteria were patients who could not speak, had previous gustatory and olfactory dysfunctions or whose PCR tests for SARS-CoV-19 were negative.
INTERVENTIONS: Systematic assessment of gustatory and olfactory symptoms with standardised questions.
OUTCOMES: Prevalence of gustatory and olfactory dysfunctions in patients with COVID-19 pneumonia.
RESULTS: Of the 80 study subjects, 62.5% were male and the median age was 57 years. Half of the cohort (n=40) presented with comorbidities. The prevalence of chemosensitive disorder was 73.8% (n=59) (95% CI: 63.8 to 83.8), although self-reported symptoms were recorded in only 26.3% (n=21) of patients in the ER. Gustatory and olfactory dysfunctions were observed in 58.8% (n=47) and 55% (n=44) of cases, respectively. They were also the first symptoms in 25% (n=20) of patients. Anosmia was associated with ageusia, OR: 7, 95% CI: 2.3 to 21.8, p=0.001). No differences in clinical outcomes were observed when patients with and without gustatory and olfactory dysfunctions were compared. Recovery rates were 20% (n=10) and 85% (n=42) at days 7 and 45, respectively.
CONCLUSION: The prevalence of gustatory and olfactory dysfunctions in COVID-19 pneumonia was much higher than in self-report. Presence of gustatory and olfactory dysfunctions was not a predictor of clinical outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
BMJ open - 11(2021), 8 vom: 17. Aug., Seite e040775 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Inciarte, Alexy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult otolaryngology |
|---|
| Anmerkungen: |
Date Completed 23.08.2021 Date Revised 03.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2020-040775 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329482742 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329482742 | ||
| 003 | DE-627 | ||
| 005 | 20240403232857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2020-040775 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM329482742 | ||
| 035 | |a (NLM)34404693 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Inciarte, Alexy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia |b a prospective study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2021 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a IMPORTANCE: Identifying undetected clinical signs is imperative in the prevention of SARS-CoV-2 | ||
| 520 | |a OBJECTIVE: To establish the prevalence of clinical gustatory and olfactory dysfunctions in patients with COVID-19 pneumonia. Clinical outcomes and recovery rates associated with gustatory and olfactory dysfunctions were also assessed | ||
| 520 | |a DESIGN: A prospective study was performed in 80 patients admitted to Hospital Clínic of Barcelona (Spain) for COVID-19 pneumonia. Patients were re-evaluated in the ward daily until discharge. Gustatory and olfactory dysfunction symptoms were retrospectively collected from emergency room (ER) charts after first assessments. Follow-up was performed in telemedicine consultation | ||
| 520 | |a SETTING: The single-centre study was performed in a hospitalisation ward at a university hospital | ||
| 520 | |a PARTICIPANTS: Consecutive patients meeting hospitalisation criteria for COVID-19 pneumonia were eligible. Study exclusion criteria were patients who could not speak, had previous gustatory and olfactory dysfunctions or whose PCR tests for SARS-CoV-19 were negative | ||
| 520 | |a INTERVENTIONS: Systematic assessment of gustatory and olfactory symptoms with standardised questions | ||
| 520 | |a OUTCOMES: Prevalence of gustatory and olfactory dysfunctions in patients with COVID-19 pneumonia | ||
| 520 | |a RESULTS: Of the 80 study subjects, 62.5% were male and the median age was 57 years. Half of the cohort (n=40) presented with comorbidities. The prevalence of chemosensitive disorder was 73.8% (n=59) (95% CI: 63.8 to 83.8), although self-reported symptoms were recorded in only 26.3% (n=21) of patients in the ER. Gustatory and olfactory dysfunctions were observed in 58.8% (n=47) and 55% (n=44) of cases, respectively. They were also the first symptoms in 25% (n=20) of patients. Anosmia was associated with ageusia, OR: 7, 95% CI: 2.3 to 21.8, p=0.001). No differences in clinical outcomes were observed when patients with and without gustatory and olfactory dysfunctions were compared. Recovery rates were 20% (n=10) and 85% (n=42) at days 7 and 45, respectively | ||
| 520 | |a CONCLUSION: The prevalence of gustatory and olfactory dysfunctions in COVID-19 pneumonia was much higher than in self-report. Presence of gustatory and olfactory dysfunctions was not a predictor of clinical outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a adult otolaryngology | |
| 650 | 4 | |a infection control | |
| 650 | 4 | |a infectious diseases | |
| 650 | 4 | |a public health | |
| 650 | 4 | |a respiratory infections | |
| 700 | 1 | |a Cardozo, Celia |e verfasserin |4 aut | |
| 700 | 1 | |a Chumbita, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Alcubilla, Pau |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Berta |e verfasserin |4 aut | |
| 700 | 1 | |a González Cordón, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Rico, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Aguero, Daiana |e verfasserin |4 aut | |
| 700 | 1 | |a García-Pouton, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Meneses, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Albiach, Laia |e verfasserin |4 aut | |
| 700 | 1 | |a Meira, Fernanda |e verfasserin |4 aut | |
| 700 | 1 | |a De la Mora, Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a Linares, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Puerta-Alcalde, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Macaya, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Mensa, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a Laguno, Montse |e verfasserin |4 aut | |
| 700 | 1 | |a Ambrosioni, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Morata, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Bodro, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-García, Estela |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Sola, Montse |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas, Jhon |e verfasserin |4 aut | |
| 700 | 1 | |a Leal, Lorna |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Vidal, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Jose Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Alobid, Isam |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Felipe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2011 |g 11(2021), 8 vom: 17. Aug., Seite e040775 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:8 |g day:17 |g month:08 |g pages:e040775 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2020-040775 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 8 |b 17 |c 08 |h e040775 | ||